PD-L1 Binding Small Molecules Block T Cell Exhaustion

The patent uses small molecule compounds as intermediaries that bind to PD-L1 and prevent its interaction with PD-1 and CD80. These compounds act as mediators that block the inhibitory signal transmission, restoring T cell function without directly stimulating the immune system. The compounds interfere with the protein-protein interaction interface, effectively separating the harmful inhibitory signal from the T cell receptor.

The patent extracts the inhibitory function from the PD-L1 molecule by using compounds that specifically bind to PD-L1 and prevent it from interacting with PD-1 and CD80. This extraction removes the harmful inhibitory effect while leaving the PD-L1 molecule intact for other functions. The small molecules selectively isolate and block the inhibitory interaction pathway.

The patent replaces expensive, complex monoclonal antibodies with smaller, simpler small molecule compounds. These small molecules are less complex to manufacture, can be administered more easily, and have lower costs. The compounds are designed to be orally active and require no specialized delivery systems, simplifying the treatment protocol while maintaining the PD-L1 blocking function.

The patent substitutes the biological mechanism of monoclonal antibodies with a chemical mechanism involving small molecule compounds. Instead of using protein-based antibodies that require complex purification and formulation, the invention uses small organic molecules that can be synthesized more simply and administered through conventional oral or injectable formulations. This substitution simplifies the overall treatment system.

The patent achieves local specificity by designing compounds that selectively bind to PD-L1 at its interaction interface with PD-1 and CD80. The small molecules are structured to fit precisely into the binding cleft, providing selective blocking of the inhibitory interaction. This local quality ensures that only the specific PD-L1/PD-1 and PD-L1/CD80 interactions are blocked, minimizing off-target effects while maintaining immune response enhancement.

The patent optimizes the binding affinity and selectivity parameters of the small molecule compounds to achieve high specificity for PD-L1. By tuning the chemical structure to optimize binding parameters, the compounds can selectively block PD-L1 interactions without affecting other immune pathways. This parameter optimization reduces off-target effects while maintaining therapeutic efficacy.